Health Care • Medical Specialities
$298.41 ▲ +3.41
(+1.16%)
MKT CAP: $78.85B • VOL: 1.27M
52W L $240 52W H $316
CI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $274.90B | $247.12B | $195.26B |
| YoY Revenue Growth % | +11.2% | +26.6% | — |
| Gross Profit | $59.91B | $64.61B | $85.92B |
| Gross Margin % | 21.8% | 26.1% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $9.20B | $9.42B | $8.54B |
| Operating Margin % | 3.3% | 3.8% | 4.4% |
| Net Income (GAAP) | $5.96B | $3.43B | $5.16B |
| EBITDA (Normalized) | $19.10B | $18.31B | $15.57B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $9.60B | $10.36B | $11.81B |
| Capital Expenditures (CapEx) | $12.37B | $11.12B | $8.79B |
| Free Cash Flow (FCF) | -$2.77B | -$757.4M | $3.03B |
| FCF Margin % | -1.0% | -0.3% | 1.5% |
| Return on Invested Capital (ROIC %) | 8.4% | 8.7% | 4.8% |
| Cash & Short-Term Equivalents | $7.68B | $7.55B | $25.77B |
| Total Debt (Short + Long Term) | $52.22B | $51.59B | $54.83B |
| Total Stockholders' Equity | $41.71B | $41.03B | $112.47B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CI.